Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+16%
CX
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
+16%
ACAD
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+11%
PLKI
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

jb-vertical


Top Catalysts For The Week Ending February 17 2017


LightPath Technologies = Beats on earnings and revenue

Editas Medicine = Patent Office Decision Favorable to Broad Institute in CRISPR

Agilent Technologies = Beats on Earnings and Revenue

IPG Photonics = Beats on earnings and revenue

Sonus Networks = Rising Money Flow On Institutional Buying

KapStone Paper = Confirms Raising Containerboard Prices

Popeyes Louisiana Kitchen = Hearing Takeover Rumors Circulating

XPO Logistics = Rising Revenue and Money Flow


Trading Lessons

Mainstream Financial News

Archives

Alexion Pharmaceuticals Seeing Heavy Call Activity

Follow Us on StockTwits

January 4, 2017: Seeing heavy call activity in Alexion Pharmaceuticals: 2,000 Aug $140 calls traded at $12.80. I wonder if the heavy call activity has anything to do with the takeover rumors that were circulating on December 20, 2016, about Alexion Pharmaceuticals?

December 22, 2016: Leerink defending Alexion Pharmaceuticals; Reiterates outperform rating and price target of $211. Leerink says that the failure of Soliris for the prevention of delayed graft function (DGF) after kidney transplantation does not materially impact firms long-term Soliris forecasts or growth rate, but does represent another example of Alexion ploughing Soliris profits into high risk trials for low value indications. DGF represented less than $50M of annual global sales for their long-term Soliris forecasts (previous probability of success was 35%), and the removal does not impact firms valuation.

December 20, 2016: Hearing takeover rumors circulating about biotechnology firm Alexion Pharmaceuticals. The rumor is that a big (but unnamed) drug company has approached Alexion Pharmaceuticals with a takeover offer. The rumor is that Roche could be still interested in Alexion. The rumors are likely coming from this story: http://www.streetinsider.com/Hot+M+and+A/Alexion+Pharmaceuticals+%28ALXN%29+Said+to+Receive+Takeover+Approach+-+Source/12360443.html

I put a lot of credibility on this takeover rumor because the CEO Hallal left the company on 12/12/16 for “personal reasons” and CFO Sinha also left the company to “pursue other opportunities.” Sometimes when high-ranking officers in a company start leaving all of a sudden, something big is going on.

Alexion Pharmaceuticals Stock Chart


The Finviz screener settings used to find Alexion Pharmaceuticals are: Sector Healthcare, Sales growth past 5 years Over 30%, EPS growth qtr over qtr 100% – 200%, Gross Margin High (>50%)

Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development, and commercialization of life-transforming therapeutic products.

StockTwits

Trading The News: Alexion Pharmaceuticals In The News